Genmab reported DKK1.07B in Gross Profit on Sales for its fiscal quarter ending in June of 2026.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Almirall EUR 429.87M 180.02M Dec/2025
Amarin USD 23.17M 961K Dec/2025
Amgen USD 5.87B 1.02B Mar/2026
argenx SE USD 1.18B 40.98M Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
Bayer EUR 6.33B 1.84B Jun/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Demant DKK 9.96B 1.13B Jun/2026
Exelixis USD 608.03M 17.17M Jun/2026
Fresenius Medical Care EUR 1.31B 130.98M Jun/2026
Genmab DKK 1.07B 240M Jun/2026
GlaxoSmithKline GBP 6.51B 757M Jun/2026
GN Store Nord DKK 1.13B 116M Jun/2026
GRIFOLS EUR 704M 84M Jun/2026
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Insmed USD 356.19M 99.73M Jun/2026
Lakefront Biotherapeutics EUR 1.68M 898.68M Mar/2026
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.17B 101M Jun/2026
Novartis USD 11.24B 1.18B Jun/2026
Regeneron Pharmaceuticals USD 3.71B 778.2M Jun/2026
Roche Holding CHF 22.69B 600M Jun/2026
Sanofi EUR 8.71B 602M Jun/2026
UCB EUR 3.19B 621M Dec/2025